In its 16th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2020 and analyzes funding trends spanning twenty years.
hivresourcetracking.org
The most up-to-date and comprehensive field-wide estimates for HIV prevention and R&D globally.
Pregnant and Lactating People (PLP) in Ongoing HIV Prevention Trials
Current trends for investment in HIV prevention R&D by technology
Status Updates on Ongoing and Planned HIV Prevention Trials
The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.
How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.
AIDS Vaccines by the Numbers: Trials, discoveries, money and more
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.
HIV Vaccines: An introductory factsheet
This is an updated introductory two-page document that describes HIV vaccines research and reviews key developments in the field.